Kopp Family Office’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.84M | Sell |
203,230
-2,177
| -1% | -$30.4K | 1.84% | 18 |
|
|
2025
Q1 | $2.77M | Hold |
205,407
| – | – | 1.91% | 16 |
|
|
2024
Q4 | $3.94M | Sell |
205,407
-330
| -0.2% | -$6.33K | 2.5% | 12 |
|
|
2024
Q3 | $4.68M | Hold |
205,737
| – | – | 2.98% | 13 |
|
|
2024
Q2 | $2.68M | Buy |
205,737
+97
| +0% | +$1.26K | 1.66% | 12 |
|
|
2024
Q1 | $3.6M | Buy |
205,640
+40
| +0% | +$700 | 2.06% | 12 |
|
|
2023
Q4 | $4.48M | Sell |
205,600
-8,690
| -4% | -$189K | 2.62% | 12 |
|
|
2023
Q3 | $3.29M | Hold |
214,290
| – | – | 2.08% | 12 |
|
|
2023
Q2 | $5.1M | Buy |
214,290
+83,002
| +63% | +$1.97M | 2.74% | 12 |
|
|
2023
Q1 | $3.34M | Buy |
131,288
+66,900
| +104% | +$1.7M | 1.8% | 12 |
|
|
2022
Q4 | $1.88M | Buy |
+64,388
| New | +$1.88M | 1.13% | 11 |
|